Fundraising Fox
Emergo Therapeutics
Durham, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into Emergo Therapeutics
Sign up to see every warm intro you have to Emergo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Emergo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases. Its pharmaceutical programs address acute and chronic conditions including flu/influenza-like illness and Long COVID, with clinical trials conducted in coordination with the FDA.
Founders & leadership
Emergo Therapeutics was founded in 2016 by Robin Hyde-DeRuyscher.
RH
Robin Hyde-DeRuyscherCSO, President and FounderHe brings experience in biotechnology research, drug development, manufacturing, and regulatory affairs, with background in biologics production, team leadership, and process development across multiple sites.
MK
Moise KhayrallahCEOMoise Khayrallah is CEO of Emergo Therapeutics, which develops immunomodulatory drugs targeting inflammatory cytokine production across acute and chronic conditions. He brings over 35 years of pharmaceutical industry experience across large-scale pharma, contract research organizations, and biotechnology companies.
MP
Margaret PowellNamed on SEC filing
RH
Robert HelmedagNamed on SEC filing
JE
John E. Bailey, Jr.Named on SEC filing
Investors · 4
Rex Health Ventureslisted by Rex Health VenturesRaleigh · $250K – $500K
How we know: Rex Health Ventures's portfolio page · funding news · Not right? Tell us
Wolfpack Investor Networklisted by Wolfpack Investor NetworkRaleigh · $250K – $5M
How we know: Wolfpack Investor Network's portfolio page · funding news · Not right? Tell us
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
How we know: the VCSheet dataset · Not right? Tell us
VentureSouthreportedGreenville
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$16M disclosed across 3 rounds · 2018–2022
▶$500KraisedMay 2022 · 2 investors · PharmaceuticalsRule 506(b)
▶$500KraisedMay 2022 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- John E. Bailey, Jr.Director
- Moise KhayrallahExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $500K
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedOct 2020 · 77 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedOct 2020 · 77 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- Moise KhayrallahExecutive Officer, Director
- John E. Bailey, Jr.Director
- Offering amount
- $5M
- Amount sold
- $3.5M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$12MraisedSep 2019 · 110 investors · PharmaceuticalsRule 506(b)
▶$12MraisedSep 2019 · 110 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret PowellDirector
- Robert HelmedagDirector
- John E. Bailey, Jr.Director
- Moise KhayrallahExecutive Officer, Director
- Robin Hyde-DeRuyscherExecutive Officer
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $10K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Apogee TherapeuticsApogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
Protego BiopharmaProtego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
SynthegoSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Companies working in the same space as Emergo Therapeutics.
Frequently asked questions
- What does Emergo Therapeutics do?
- Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases. Its pharmaceutical programs address acute and chronic conditions including flu/influenza-like illness and Long COVID, with clinical trials conducted in coordination with the FDA.
- Who founded Emergo Therapeutics?
- Emergo Therapeutics was founded by Robin Hyde-DeRuyscher in 2016.
- Who are Emergo Therapeutics's investors?
- Emergo Therapeutics's investors include Rex Health Ventures, Wolfpack Investor Network, Hatteras Venture Partners, VentureSouth.
- How much funding has Emergo Therapeutics raised?
- Emergo Therapeutics has disclosed $16M raised across 3 rounds.
- Where is Emergo Therapeutics headquartered?
- Emergo Therapeutics is headquartered in Durham, US.